A Randomized, Blinded, Controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of a COVID-19 mRNA Vaccine (ZSVG-02-O) in a Healthy Population 18 Years of Age and Older
Latest Information Update: 14 Nov 2023
At a glance
- Drugs ZSVG 02 O (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors Virogin Biotech
Most Recent Events
- 09 Nov 2023 New trial record